Drug intelligence / Profile preview

BOW090

Development stage: Preclinical
Lead developer: Epirus Biopharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

BOW090 is a proposed biosimilar of ustekinumab, a fully human IgG1 kappa monoclonal antibody that targets the p40 subunit shared by interleukin‑12 (IL‑12) and interleukin‑23 (IL‑23), thereby inhibiting downstream Th1 and Th17 inflammatory pathways. It was developed in the preclinical stage within the Bioceros CHOBC platform and acquired by Epirus Biopharmaceuticals as part of an expanded biosimilar pipeline, with the intent to mirror ustekinumab’s use in inflammatory and immune‑mediated disorders such as psoriasis, psoriatic arthritis, and Crohn’s disease.[4][10][7][12]

Targets

IL12B (Interleukin-12/23 p40 subunit)

Beyond the preview

Go deeper on BOW090.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BOW090.

Explore the full profile